Lung Cancer
Roy S. Herbst, John Victor Heymach, Scott Michael Lippman · New England Journal of Medicine · 2008
The Molecular Origins of Cancer series continues with this review of molecular and genetic mechanisms of lung cancer. The authors review genetic susceptibility to lung cancer and four genes of importance in the evolution of the disease: EGFR, KRAS, the PI3K–Akt–mTOR complex, and TITF1. They also discuss gene profiling and protein profiling, with emphasis on the clinical value of these methods.
Cited by 2,389 works. doi:10.1056/nejmra0802714 Open-access PDF
Authors
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Cancer Statistics, 2008
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling